Completed PHASE2 INTERVENTIONAL 4-arm NCT00123305

Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke

A Multicentre, Double-Blind, Placebo-Controlled, Ascending-dose, Clinical Trial of Intravenous Microplasmin Administration in Patients With Acute Ischemic Stroke

Sponsor: ThromboGenics

Conditions Stroke, Acute

Interventions Microplasmin

Updated 6 times since 2017 Last updated: Nov 6, 2014 Started: Oct 31, 2005 Primary completion: May 31, 2008 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00123305, this PHASE2 trial focuses on Stroke, Acute and remains completed. Sponsored by ThromboGenics, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ThromboGenics

Data source: ThromboGenics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Brussels, Belgium , Erlangen, Germany , Essen, Germany , Frankfurt, Germany , Freiburg im Breisgau, Germany , Graz, Austria , Göttingen, Germany , Hamburg, Germany , Leipzig, Germany , Leuven, Belgium and 4 more locations